Kalijev Klorid B. Braun

Potassium chloride, the active ingredient in Kalijev Klorid B. Braun, is an electrolyte presented as an intravenous solution for intravenous use. It treats hypokalemia and provides potassium replacement in patients who require restoration of normal electrolyte balance, such as those with cardiac arrhythmias or postoperative potassium loss.

GNH USA supplies Kalijev Klorid B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU pharmaceutical standards and is distributed across European and global markets.

Kalijev Klorid B. Braun, a potassium chloride intravenous solution, is employed to correct electrolyte disturbances associated with low potassium levels.

- Hypokalemia: restores normal serum potassium concentrations, helping to prevent muscle weakness and cardiac complications. - Potassium replacement therapy: provides controlled potassium supplementation for patients requiring electrolyte repletion. - Diuretic‑induced potassium loss: compensates for potassium depletion caused by loop or thiazide diuretics. - Post‑operative potassium depletion: replenishes potassium lost during surgical procedures and anesthesia.

Intravenous potassium chloride may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion site pain or irritation: mild discomfort at the injection site. - Nausea or vomiting: gastrointestinal upset occurring during or after infusion. - Headache: transient headache reported by some patients. - Muscle weakness or tingling: mild neuromuscular sensations.

Serious or Rare Side Effects: - Severe hyperkalemia: excessive rise in serum potassium that can cause cardiac arrest. - Cardiac arrhythmias: life‑threatening rhythm disturbances such as ventricular fibrillation. - Anaphylactic reaction: rare hypersensitivity leading to airway compromise and hypotension.

When using Kalijev Klorid B. Braun, several precautions should be observed to ensure safe administration.

- Assess serum potassium: verify baseline potassium levels before initiating therapy. - Monitor cardiac rhythm: continuous ECG monitoring is recommended during infusion. - Adjust infusion rate in renal impairment: slow infusion and dose reduction are required for patients with reduced kidney function. - Avoid rapid bolus administration: administer over the recommended time to prevent hyperkalemia. - Use compatible IV solutions: ensure the diluent does not contain calcium or other contraindicated substances. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Potassium chloride can interact with several medications, affecting potassium balance or cardiac function.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may cause additive hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of dangerous potassium elevation. - NSAIDs: can reduce renal potassium excretion, enhancing hyperkalemia risk. - Digoxin: elevated potassium levels may potentiate digoxin toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hyperkalemia. - Calcium channel blockers: combined effect on cardiac conduction may require monitoring. - Trimethoprim‑sulfamethoxazole: can impair renal potassium handling. - IV fluids containing potassium: cumulative potassium load should be calculated.